Minerva Biolabs GmbH

Contamination by mycoplasma and other microorganisms is a major risk in cell culture and biopharmaceutical production, and this company provides solutions to detect, prevent and eliminate contamination using conventional PCR, real-time PCR and digital PCR. Its portfolio includes sample preparation kits, reference standards, DNA decontamination products and tools for (q)PCR qualification, along with PCR-based quality control tests for cell and gene therapies, including residual DNA testing, viral vector titre and vector copy number (VCN) analysis, as well as monocyte activation tests for pyrogen testing.